卵巢癌细胞以节拍式给药暴露于ATR抑制剂AZD6738后导致CDC25A表达缺失并对ATRi治疗耐药
本研究通过节拍式给药AZD6738诱导卵巢癌细胞(OVCAR3和OV90)对ATR抑制剂耐药,发现耐药细胞对Chk1抑制剂LY2603618交叉耐药,但对奥拉帕利或顺铂联合不交叉耐药;耐药细胞在AZD6738处理后出现G1/S期阻滞,CDC25A缺失介导耐药,血清蛋白组学鉴定出GC、APOE和APOA1在耐药背景中显著升高。
要点
- 节拍式AZD6738给药诱导的卵巢癌细胞对ATR/Chk1抑制剂耐药,但对奥拉帕利或顺铂联合不交叉耐药。
- 耐药细胞在AZD6738处理后出现G1/S期阻滞,且与帕博西利联合赋予对AZD6738的耐药。
- CDC25A表达缺失是卵巢癌细胞对ATRi耐药的机制之一,血清GC、APOE和APOA1在耐药背景中显著升高。
核心结论
- 卵巢癌细胞以AZD6738节拍式给药导致对ATR/Chk1抑制剂耐药,CDC25A表达缺失是ATRi耐药机制之一,并鉴定出CDC25A低表达、AZD6738耐药卵巢癌细胞的循环生物标志物候选物。
研究设计与样本
- 通过AZD6738给药生成ATR抑制剂耐药的卵巢癌细胞(OVCAR3和OV90),评估对Chk1抑制剂LY2603618、PARP抑制剂奥拉帕利及与顺铂或CDK4/6抑制剂帕博西利联合的敏感性。
- 采用多种方法表征模型,包括在OV90细胞中沉默CDC25A并评估对ATRi反应的影响;对ATR抑制剂耐药的OV90异种移植瘤进行血清蛋白质组学分析以鉴定ATRi耐药的循环生物标志物候选物。
主要发现
- AZD6738耐药细胞系对LY2603618难治,但对奥拉帕利或与顺铂联合不耐药。
- 细胞周期分析显示ATR抑制剂耐药细胞在AZD6738处理后出现G1/S期阻滞;与帕博西利联合赋予对AZD6738的耐药。
- AZD6738耐药细胞G1/S期调控蛋白丰度改变,包括AZD6738耐药OV90细胞中CDC25A缺失;在OV90细胞中沉默CDC25A赋予对AZD6738的耐药。
- AZD6738耐药OV90异种移植瘤的血清蛋白质组学鉴定出维生素D结合蛋白(GC)、载脂蛋白E(APOE)和载脂蛋白A1(APOA1)在AZD6738耐药背景中显著升高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: ATR kinase inhibitors promote cell killing by inducing replication stress and through potentiation of genotoxic agents in gynecologic cancer cells. To explore mechanisms of acquired resistance to ATRi in ovarian cancer, we characterized ATRi-resistant ovarian cancer cells generated by metronomic dosing with the clinical ATR inhibitor AZD6738. METHODS: ATRi-resistant ovarian cancer cells (OVCAR3 and OV90) were generated by dosing with AZD6738 and assessed for sensitivity to Chk1i (LY2603618), PARPi (Olaparib) and combination with cisplatin or a CDK4/6 inhibitor (Palbociclib). Models were characterized by diverse methods including silencing CDC25A in OV90 cells and assessing impact on ATRi response. Serum proteomic analysis of ATRi-resistant OV90 xenografts was performed to identify circulating biomarker candidates of ATRi-resistance. RESULTS: AZD6738-resistant cell lines are refractory to LY2603618, but not to Olaparib or combinations with cisplatin. Cell cycle analyses showed ATRi-resistant cells exhibit G1/S arrest following AZD6738 treatment. Accordingly, combination with Palbociclib confers resistance to AZD6738. AZD6738-resistant cells exhibit altered abundances of G1/S phase regulatory proteins, including loss of CDC25A in AZD6738-resistant OV90 cells. Silencing of CDC25A in OV90 cells confers resistance to AZD6738. Serum proteomics from AZD6738-resistant OV90 xenografts identified Vitamin D-Binding Protein (GC), Apolipoprotein E (APOE) and A1 (APOA1) as significantly elevated in AZD6738-resistant backgrounds. CONCLUSIONS: We show that metronomic dosing of ovarian cancer cells with AZD6738 results in resistance to ATR/ Chk1 inhibitors, that loss of CDC25A expression represents a mechanism of resistance to ATRi treatment in ovarian cancer cells and identify several circulating biomarker candidates of CDC25A low, AZD6738-resistant ovarian cancer cells.
引用
- Ao W, Kim HI, Tommarello D, et al. Metronomic dosing of ovarian cancer cells with the ATR inhibitor AZD6738 leads to loss of CDC25A expression and resistance to ATRi treatment. Gynecol Oncol. 2023. PMID: 37639904. doi:10.1016/j.ygyno.2023.08.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。